City Therapeutics lands $200M IPO as it builds an Alnylam 2.0 in RNAi field
City Therapeutics will be the 26th biotech to complete an initial public offering in 2026 when it begins trading Friday morning, adding to a boisterous …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Source link







